Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha Lipoic Acid to Decrease Treatment Related Pain and Side Effects During Concurrent Chemoradiation in HNSCC
NCT04042935Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alpha-lipoic acid in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Colorado Denver. Primary endpoints: Maximum Tolerated Dose at 18 months and Recommended Phase 2 Dose at 18 months. Started Feb 2020; status: completed.
02
Drugs
alpha-lipoic acid
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04042935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042935.